Blinatumomab Liquid
NDC Package 17504-0011-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Blinatumomab liquids is a medication used to treat a certain type of cancer (acute lymphocytic leukemia-ALL). This formulation utilizes a liquid delivery system. Marketed by Lonza Biologics, Plc, this product is identified by NDC 17504-0011.

Identification & Billing

NDC Package Code
17504-0011-1
Package Description
4234 mL in 1 BOTTLE
Product Code
17504-0011
11-Digit Billing Format
17504001101

Clinical Specifications

Proprietary Name
Blinatumomab
Non-Proprietary Name
Blinatumomab
Substance Name
Blinatumomab
Dosage Form
Liquid - A dosage form consisting of a pure chemical in its liquid1 state. This dosage form term should not be applied to solutions.
Active Ingredient(s)
BLINATUMOMAB 55 ug/mL
Usage Information
This medication is used to treat a certain type of cancer (acute lymphocytic leukemia-ALL). Blinatumomab belongs to a class of drugs known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Lonza Biologics, Plc
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
12-18-2014
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 17504-0011-1 identifies a specific commercial package of 4234 ml in 1 bottle of Blinatumomab (UNFINISHED drug), drug for further processing labeled by Lonza Biologics, Plc. This liquid is formulated for use and contains blinatumomab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lonza Biologics, Plc on December 18, 2014. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat a certain type of cancer (acute lymphocytic leukemia-ALL). Blinatumomab belongs to a class of drugs known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells.

How is this Lonza Biologics, Plc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 17504001101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
17504-0011-1
11-Digit CMS (5-4-2)
17504-0011-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.